ImmuCell (ICCC) director awarded 10,000 options at $5.49 exercise price

Rhea-AI Filing Summary

ImmuCell Corp director David Scott Tomsche received a grant of 10,000 stock options as compensation. These non-qualified stock options give him the right to buy 10,000 shares of ImmuCell common stock at an exercise price of $5.49 per share. Following this award, his reported derivative holdings from this grant total 10,000 options, which become exercisable on April 16, 2028 and expire on April 16, 2030. This is a routine equity incentive award rather than an open-market share purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Tomsche David Scott

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Non Qualified Stock Options (Right to buy)	10,000	$0.00	--

Holdings After Transaction: Non Qualified Stock Options (Right to buy) — 10,000 shares (Direct)

Footnotes (1)

Key Figures

Options granted: 10,000 options Exercise price: $5.49 per share Derivative holdings after grant: 10,000 options +2 more

5 metrics

Options granted 10,000 options Non-qualified stock options granted to director

Exercise price $5.49 per share Right to buy ImmuCell common stock

Derivative holdings after grant 10,000 options Total options reported following transaction

Exercise start date April 16, 2028 Option exercise date

Expiration date April 16, 2030 Option expiration date

Key Terms

Non Qualified Stock Options, exercise price, expiration date, derivative securities

4 terms

Non Qualified Stock Options financial

"Non Qualified Stock Options (Right to buy)"

exercise price financial

"conversion_or_exercise_price: "5.4900""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2030-04-16T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

derivative securities financial

"derivativeTransactionCount: 1"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tomsche David Scott

(Last) (First) (Middle)

C/O IMMUCELL CORPORATION

56 EVERGREEN DRIVE

(Street)

PORTLAND MAINE 04103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IMMUCELL CORP /DE/ [ ICCC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/16/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non Qualified Stock Options (Right to buy)	$5.49	04/16/2025		A		10,000		04/16/2028	04/16/2030	Common Stock	10,000	$0	10,000	D

Explanation of Responses:

Remarks:

The options were granted by the Issuer to compensate directors for services on the Issuer's board of directors.

	/s/ Timothy C. Fiori Attorney-in-Fact	04/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did ImmuCell (ICCC) director David Scott Tomsche report on this Form 4?

David Scott Tomsche reported receiving 10,000 non-qualified stock options as compensation. These options give him the right to buy 10,000 ImmuCell common shares at an exercise price of $5.49 per share, subject to the stated vesting and expiration dates.

Are the ImmuCell (ICCC) options granted to David Scott Tomsche an open-market purchase?

No, the 10,000 options are a grant classified as a compensation award, not an open-market purchase. The transaction uses code A, described as a grant, award, or other acquisition, with a $5.49 exercise price set for future potential share acquisition.

What are the key terms of David Scott Tomsche’s 10,000 ImmuCell (ICCC) options?

The grant covers 10,000 non-qualified stock options on ImmuCell common stock with a $5.49 exercise price. The options are exercisable starting April 16, 2028 and expire on April 16, 2030, defining a two-year exercise window once vesting begins.

How many ImmuCell (ICCC) derivative securities does David Scott Tomsche hold after this grant?

After this reported grant, total derivative securities from this award are 10,000 options. The Form 4 shows 10,000 non-qualified stock options following the transaction, all with the same $5.49 exercise price tied to ImmuCell common stock.

Does this ImmuCell (ICCC) Form 4 indicate any share sales by David Scott Tomsche?

No, the filing shows no sales of ImmuCell shares. It reports only an acquisition of 10,000 non-qualified stock options as a grant, with no corresponding sale or disposition transactions disclosed in the provided data.